Notes

A news scan found the headline about testing the exact text that survives scheduled-job journaling, not just the script exit code: SRRK job26 exited 0 but its saved output cut off before issuer RSS. The system puts current primary headlines first and keeps output bounded; replacement job27 was tested at 1091 bytes, with the first sandbox execution still pending.

Read the FDA response letter before treating a manufacturing-only headline as a completed approval checklist: SRRK's September 22, 2025 letter also requires labeling and safety updates. Never transfer deficiencies at a removed plant to its unnamed replacement, or turn one completed FDA window into a calibrated resubmission edge.

A positive point estimate does not override the uncertainty gate: HITI's 11-event gain of 3.76% fell to 0.39% under execution stress, which is a test of how well a strategy works when actually used, and its mean-return 95% interval, a range of likely outcomes, spanned -0.73% to +1.53%. Keep size zero until independent evidence improves; the monthly shortfall is not evidence.

Check timestamps and monitor acknowledgements before relying on coverage: only 8,066 of 12,436 priced US listings had September 4 bars, and the 20-monitor cap rejected five reviews. Retain stale or missing exclusions and failed-monitor status explicitly; use tested journal collection for overflow, never imply it can execute an exit.

Separate scheduled earnings from the information already released: HITI's current quarter was preannounced, while only one of the 11 holdout events matched that preannouncement regime. Require a prospectively defined comparable sample before treating the pooled 63.64% win rate as an event-specific edge.

The manager will not increase investment in a fragile overlay for LEN because its average return of 0.1815% is not strong enough, with a possible range of -1.4967% to 1.7908%. This means the investment size will remain at zero, even though LEN has won 60% of the time in the past. The current monthly loss does not change this decision, and it is not a good reason to buy a share of ASO, which is affordable but untested.

A small positive backtest must survive plausible execution costs. LEN's fixed ATR-exit holdout gained 1.47% across 10 trades at 15bp per side, but lost 1.53% at 30bp per side. Require consolidated or verified executable price coverage before using daily IEX stop touches as fill evidence; never fill missing bars by shifting event sessions.

A news scan found the note that anchor earnings tests should be based on the release notice, not the call calendar. For example, LEN releases its earnings on September 16 after the market close, which is a day before its call on September 17. Additionally, the 2022 holiday notice also changed the timing. When an old plan, also known as a roadmap, conflicts with newer decisions made by developers, who are the people creating the system, follow the most recent decision record, which is a document that keeps track of decisions, and verify the final setup, also known as configuration, before asserting, or confirming, an activation epoch, which is a point in time when something is started.

On a closed-market trading run with no holdings, orders or due monitors, check saved eligibility before queuing an order across a holiday: all three audited rules still sized to zero, and the next research run precedes the next stock session. Retain future research monitors without treating their review times as automatic entry or release times.

A plausible approval case cannot override a failed trading rule: GRAL's 13-trade holdout lost 36.22%, with 30.77% wins, 7.55% average wins and 7.74% average losses. This means that even if there is a good reason to approve a trade, if the trading rule fails, it should not be overridden. In this case, the trading rule failed, so the allocation should be kept at zero, rather than changing the parameters that were inspected or using the monthly shortfall to justify a recovery trade.

When making investment decisions based on advisory panel meetings, consider the risk from the first public briefing and all earlier company presentations, not just the vote date. For example, Galleri had a presentation on September 14 before its September 23 panel, and the FDA does not guarantee when the briefing will be made public. If a stock's book value is $49.14, it cannot be used to buy a whole share of GRAL stock priced at $80.34, so it is best to pass on the investment when the required exit access is unavailable.

For screening catalysts, record both the safety denominator, which is a measure of risk, and ascertainment window, which is a period of time used to gather data. Galleri's less than 1% all-screened invasive-procedure rate does not describe the positive-result subgroup, and a post-lock serious event supersedes an earlier no-event headline. Preserve overlapping cohorts, which are groups of people, and source discrepancies instead of converting them into independent confirmation or approval odds.

To understand how well a trading strategy worked, we need to make sure we are comparing the same things. This means we should look at the payoff, which is the profit or loss, in the same units. We also need to consider the prices at which we entered and exited trades. A tool called vectorbt does not include the fees we pay to enter a trade when it calculates the payoff, but another way of calculating returns, called invested-cash returns, does include these fees. When a company makes an announcement, we should use the exact date they made it, and if there are conflicting dates, we should use the later one to avoid using information we would not have had at the time. If there are announcements on the same day that are not clear, we should leave them out.

Before treating a PDUFA date, which is a Food and Drug Administration decision deadline, as pending, check the FDA decision record and corporate status: Nuvalent was approved on July 22, 58 days before the stale September 18 target and after acquisition. Extend the pipeline-inventory rule to completed decisions and acquisitions; a calendar match alone is ineligible.

A small fund cap does not make full deployment safe: a repeat of the observed 45.86% RARE loss on $49.14 would cost $22.54, above the $8.51 equity-risk budget. Keep size zero when the independent net holdout is negative; the monthly shortfall cannot turn CHWY’s −1.72% six-event result into an edge.

Keep issuer announcement dates and exact entry/exit rows in the journal as well as local files; a vanished artifact must not leave only a headline backtest return. Correct a misleading live monitor by replacing it, as KR #13 now distinguishes the confirmed 08:00 ET call from the unconfirmed release minute.

Before describing a trial as positive in an order thesis, identify the primary endpoint, its prespecified statistical standard, and the status of secondary endpoints. For example, MIRM's PROGRESS trial had a primary endpoint with a p-value of 0.0986, which differed from the more than 99 percent result of the secondary lesion-volume endpoint. A p-value measures the probability of a result happening by chance. Extend the company-wide inventory rule to undated windows. For instance, the AZURE-1 trial in the third quarter overlapped with the September 26 PDUFA, which is a Food and Drug Administration action date, and makes a clean run-up entry ineligible.

Record an issuer-confirmed conference-call time as a call time, not an earnings-release time: KR September 11 08:00 ET is confirmed only for the call. Any future pre-event exit must account for a potentially earlier release instead of assuming the call marks the start of event risk.

A repeated headline is not new evidence: the 21:05 IONS item was already evaluated in analysis #16. On closely spaced trading runs, keep rejected sizing at zero until a changed primary fact and validated entry rule justify reconsideration; do not retune the failed three-event holdout.

When a headline lacks search-engine confirmation, open the issuer's release index directly: the September 4 pelacarsen failure was available there. Keep it unverified until the underlying release is read, and do not convert a confirmed adverse event into a rebound trade without a tested edge.

The fund manager had to sell a specific amount of MIRM shares, which was 0.6549 shares, during regular trading hours. To manage risk in biotech investments overnight, the manager needs to buy whole shares at a reasonable price and adjust the amount of shares to account for potential big price changes, or not buy any shares at all. A stop order, which automatically sells shares when they reach a certain price, does not guarantee that the sale will happen at that exact price.

The original entry price for MIRM was 99.244, with a stop loss at 93 and a target at 106, which only offered a reward to risk ratio of 1.08. This is not a good trade setup, so it is better to reject it rather than trying to adjust the target price. An operator exited the trade at a loss of 0.44%, but this does not provide enough information to determine if the original idea behind the trade would have been successful.